Trade BCAB stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
BioAtla, Inc. (BCAB) is trading at US$1.92, up 7.26% today as of Sep 21, 16:00 EDT. The company has a market capitalisation of US$5.3M. Over the past 52 weeks, BCAB has traded between US$0.12 and US$6.52. On Syfe you can trade BCAB with $0 commission and add it to your watchlist.
| Previous close | US$1.79 |
|---|---|
| Market cap | US$5.3M |
| 52-week range | US$0.12 – US$6.52 |
| Volume | 21.98K |
| Exchange | US |
Add to Watchlist
Set Price Alert
BioAtla, Inc.
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Year: 2020
Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal
May 18, 11:29 AM · MT Newswires
BioAtla, Inc. (BCAB) stock is trading at US$1.92, +7.26% from the previous close of US$1.79.
The market cap for BioAtla, Inc. (BCAB) stock is approximately US$5.3M.
The 52-week high for BioAtla, Inc. (BCAB) stock is US$6.52.
The 52-week low for BioAtla, Inc. (BCAB) stock is US$0.12.
BioAtla, Inc. (BCAB) does not currently pay a dividend.
Stay on top of BCAB
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
